The New Immunotherapies Revolutionizing Malignant Melanoma Treatment
Malignant melanoma, although representing just 1% of all skin cancer cases, is responsible for the majority of skin cancer deaths. This insidious form of cancer has witnessed rapidly increasing rates over the decades, alarming the medical community and triggering an intensive push for more effective treatments. At the forefront of this battle are researchers from the UCLA Health Jonsson Comprehensive Cancer Center, led by Dr. Antoni Ribas. His groundbreaking contributions to immunotherapy are significantly improving prognoses for those diagnosed with advanced melanoma.
Improved Survival Rates
Historically, the approach to treating cancer using immunotherapy hinged on activating the immune system's cells to target cancerous cells. This method, however, faced substantial roadblocks due to a regulatory protein called PD-1, which hampers the immune system by preventing T cells from recognizing and attacking cancer cells. The turning point in combating this issue came in 2014 with a landmark study led by Dr. Ribas.
In one of the most extensive phase 1 studies in oncology, over 600 patients with advanced melanoma were treated with pembrolizumab, a drug that targets PD-1. Known commercially as Keytruda, pembrolizumab proved revolutionary by effectively "cutting the brake lines" on the immune system, allowing it to actively attack cancer cells. This advancement changed the treatment landscape for advanced melanoma; a disease once seen as terminal now boasts a five-year survival rate nearing 50% for those who respond to this therapy.
Despite these remarkable advancements, the reality persists that immunotherapy does not work for everyone. Approximately half the patients do not respond to these therapies, which Dr. Ribas acknowledges as an area needing urgent improvement. Understanding why tumors resist these treatments and identifying patients who would or would not benefit from them are critical steps toward advancing these therapies further.
Combination Therapies
To enhance treatment efficacy, researchers, including Dr. Ribas, are exploring combination therapies. The latest studies suggest that combining immune checkpoint inhibitors with other therapeutic agents can lead to greater benefits for certain patients. A significant study co-led by Dr. Ribas examined the effects of combining two immune checkpoint inhibitors, ipilimumab and nivolumab, for patients with metastatic melanoma unresponsive to previous PD-1 therapy. This combination therapy was found to help overcome therapeutic resistance, positioning it as a preferred regimen for some melanoma cases.
Further research from the Ribas laboratory introduced a promising triple combination approach incorporating BRAF and MEK inhibitors with an immune checkpoint inhibitor in treating advanced melanoma. Clinical trials revealed that patients receiving this combination as an initial treatment saw extended periods without cancer progression.
In early-stage studies, another effective combination was identified—pembrolizumab was paired with an experimental agent designed to mimic bacterial infections. This pairing demonstrated the ability to alter the tumor's microenvironment, making it easier for the immune system to attack the cancer. Initial results showed significant tumor shrinkage in some patients, highlighting the potential of such combination therapies.
Understanding the underlying science of how immunotherapies operate is crucial, as Dr. Ribas points out, opening the door to exploring new strategies and enhancing their effectiveness for broader application.
CAR T-Cell Therapies
Building on these advances, Dr. Ribas and his team are delving into chimeric antigen receptor (CAR) T-cell therapy, a promising avenue for addressing rare and challenging melanomas. This innovative approach involves engineering a patient’s immune cells to develop synthetic receptors, enabling them to recognize and attack cancer cells displaying specific surface proteins.
Together with colleagues from Stanford and City of Hope, Dr. Ribas is exploring the potential of CAR T-cell therapy for melanomas expressing a protein called IL13Ra2. Often found in melanoma, thyroid cancers, neuroendocrine tumors, adrenocortical carcinoma, paraganglioma, and pheochromocytoma, this protein promises a new therapeutic target. The team received a substantial $10.2 million grant from the California Institute for Regenerative Medicine (CIRM) to advance their phase I clinical trial.
In collaboration with Dr. Cristina Puig-Saus, the research extends to using CAR T cells to tackle rare melanoma forms like acral, uveal, and mucosal melanoma. This approach targets cells expressing TYRP1, a protein prevalent on melanoma cell surfaces. The researchers engineered a CAR construct focused on TYRP1, and preclinical results showed these CAR T cells could effectively destroy cancer cells without causing significant side effects. Following a $5.9 million grant from CIRM, a clinical trial is in preparation to investigate the safety and efficacy of this therapy.
This work is part of Dr. Ribas' broader vision to deliver more precise and effective treatments for melanoma and other difficult-to-treat cancers. The mission is clear: to refine therapies, minimize side effects, and expand treatment options for all patients in need.
Expanding Cancer Research
The quest to develop novel immunotherapies is ceaseless within the UCLA Health Jonsson Comprehensive Cancer Center's Tumor Immunology & Immunotherapy program. As barriers in melanoma treatment fall, the focus is on innovative treatments that broaden the spectrum of therapeutic avenues. Pioneering researchers like Dr. Ribas are adept at identifying promising strategies, heralding a new era where the outlook for melanoma patients is brighter than ever before.
While the last decade has undeniably transformed the approach to melanoma treatment, it’s clear that this is only the beginning. With further breakthroughs anticipated, there is optimism for future developments that continue to push the envelope, offering hope to patients around the globe.
출처 : Original Source